Effects of the oral form of ondansetron on cerebellar dysfunction

Abstract. The aim of this study was to assess the efficacy and the safety of ondansetron administered orally in patients with a cerebellar disorder. The study was a randomised, multi-center, double-blind trial. The patients were randomised either to oral ondansetron 8 mg or to placebo twice daily for seven days. Cerebellar dysfunction was quantified before and after treatment using the International Cooperative Ataxia Rating Scale (ICARS). We performed a global analysis (total scores), we analysed by subscores (4 subscores: oculomotor, speech, kinetic, postural) and subgroups (4 subgroups: Cerebellar Cortical Atrophy (CCA), Multiple Systemic Atrophy (MSA), Familial Cerebellar Degeneration (FCD) and miscellaneous cerebellar disorders), and we also performed an analysis by individual test items. We investigated whether ondansetron and placebo had different effects upon ICARS total scores and subscores in the 4 subgroups considered together or separately. For p values < 0.05, we subsequently applied the Mann-Whitney test to compare ondansetron and placebo effect for each individual item. We evaluated 45 of the 46 patients included. No effect was found in global analysis. We found no difference in the analysis of the ICARS subscores. Concerning the individual test items, there was a significant difference between the placebo and ondansetron for the finger-to-nose test (p = 0.049), the Heel-to-Knee test (HK); (p = 0.03), the Body Sway Eyes Closed (p = 0.017) and the Body Sway Eyes Open (BSEO); (p = 0.014). There was no significant difference for tremor in upper limbs (p = 0.32) or for gait (p = 0.49). The Mann-Whitney test showed a greater effect of ondansetron than placebo for BSEO in miscellaneous disorders (p = 0.013) and for HK in FCD (p = 0.036), but ondansetron was deleterious for HK in CCA (p = 0.019). Our study showed no effect of oral ondansetron on global cerebellar dysfunction. The analysis by subgroups showed that the oral form of ondansetron (a) is deleterious for coordination in patients with CCA, (b) has no effect upon tremor in upper limbs, and (c) has a mild effect upon posture and coordination in lower limbs in some subgroups of ataxic diseases.

[1]  E. Giacobini,et al.  Cerebrospinal fluid as a reflector of central cholinergic and amino acid neurotransmitter activity in cerebellar ataxia. , 1990, Archives of neurology.

[2]  T Klockgether,et al.  The natural history of degenerative ataxia: a retrospective study in 466 patients. , 1998, Brain : a journal of neurology.

[3]  S. Lummis,et al.  Calcium changes induced by presynaptic 5-hydroxytryptamine-3 serotonin receptors on isolated terminals from various regions of the rat brain , 1999, Neuroscience.

[4]  C. Buhmann,et al.  Failure of ondansetron in treating cerebellar tremor in MS patients – an open‐label pilot study , 2001, Acta neurologica Scandinavica.

[5]  S. Young,et al.  Biogenic Amine Metabolites and Thiamine in Cerebrospinal Fluid in Heredo-Degenerative Ataxias , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[6]  G. Rice,et al.  Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[7]  P. Gatev,et al.  Use of buspirone for treatment of cerebellar ataxia. An open-label study. , 1995, Archives of neurology.

[8]  M. Krzakowski,et al.  A MULTICENTER, DOUBLE-BLIND COMPARISON OF I.V. AND ORAL ADMINISTRATION OF ONDANSETRON PLUS DEXAMETHASONE FOR ACUTE CISPLATIN-INDUCED EMESIS , 1998 .

[9]  A. Vighetto,et al.  Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. , 1997, Archives of neurology.

[10]  N P Quinn,et al.  Multiple system atrophy , 2004 .

[11]  A. Markham,et al.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. , 1996, Drugs.

[12]  J. Palo,et al.  Biogenic amine metabolites in the CSF of patients with late onset and alcoholic ataxias , 1993, Acta neurologica Scandinavica.

[13]  E. Godaux,et al.  Analysis of fast single-joint and multijoint movements in cerebellar cortical atrophy: failure of L-hydroxytryptophan to improve cerebellar ataxia. , 1997, Archives of neurology.

[14]  P. Trouillas.  The Cerebellar Serotoninergic System and its Possible Involvement in Cerebellar Ataxia , 1993, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  T. Reader,et al.  The treatment of spinocerebellar ataxias: facts and hypotheses. , 1998, Medical hypotheses.

[16]  M. Krzakowski,et al.  A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group. , 1998, Anti-cancer drugs.

[17]  G. Ebers,et al.  Ondansetron for intractable vertigo complicating acute brainstem disorders , 1995, The Lancet.

[18]  N. Barnes,et al.  Distribution and characterization of the [3H]granisetron-labelled 5-HT3 receptor in the human forebrain , 1993, Neuropharmacology.

[19]  J. Hermsdörfer,et al.  Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases. , 1995, Archives of neurology.

[20]  M. Hallett,et al.  International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome , 1997, Journal of the Neurological Sciences.

[21]  P. Adeleine,et al.  Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia. , 1997, Progress in brain research.